(Q36981698)

17 August 2017

1 reference

title

Drotrecogin alpha (activated): the treatment for severe sepsis? (English)

1 reference

17 August 2017

0 references

1 reference

1

Jean-Louis Vincent

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Biological Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

1763-1777

1 reference

Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Epidemiology of sepsis in Germany: results from a national prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Pro/con clinical debate: isolation precautions for all intensive care unit patients with methicillin-resistant Staphylococcus aureus colonization are essential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

The epidemiology of severe sepsis in children in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Sepsis in European intensive care units: results of the SOAP study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

The epidemiology of sepsis in the United States from 1979 through 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Inflammation and the activated protein C anticoagulant pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Low levels of protein C are associated with poor outcome in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Severe protein C deficiency predicts early death in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Endogenous protein C activation in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Activated protein C versus protein C in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Effects of drotrecogin alfa (activated) in human endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Clinical review: the Israeli experience: conventional terrorism and critical care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Bench-to-bedside review: the role of activated protein C in maintaining endothelial tight junction function and its relationship to organ injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

The cytoprotective protein C pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Expression and function of the endothelial protein C receptor in human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Risks and benefits of activated protein C treatment for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Assessing the use of activated protein C in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Microvascular blood flow is altered in patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Activated protein C variants with normal cytoprotective but reduced anticoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

21 January 2018

The Protein C Pathway

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1763

10.1517/14712598.7.11.1763

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference